enoblituzumab + MGA012 + MGD013
Phase 2/3Withdrawn 0 watching 0 views this week⚡ Active
57
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Head and Neck Cancer
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
Trial Timeline
Oct 1, 2019 → Oct 1, 2022
NCT ID
NCT04129320About enoblituzumab + MGA012 + MGD013
enoblituzumab + MGA012 + MGD013 is a phase 2/3 stage product being developed by MacroGenics for Head and Neck Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04129320. Target conditions include Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck.
Hype Score Breakdown
Clinical
22
Activity
15
Company
2
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04129320 | Phase 2/3 | Withdrawn |
Competing Products
20 competing products in Head and Neck Cancer